MarginsXMarginsX
Home › Data Desk › Lyell Immunopharma Inc. puts an S-3 shelf registration on file

MarginsX Data Desk · Offerings · Dilution · Cell and gene therapy · Private placement (PIPE) · Oncology

Lyell Immunopharma Inc. puts an S-3 shelf registration on file

On Nov 13, 2026, Lyell Immunopharma Inc. (LYEL) filed an S-3: a shelf registration for securities it can sell later. (SEC EDGAR, S-3, Nov 13, 2026)

By the MarginsX Data Desk, automated. Published November 14, 2026. Data as of November 13, 2026.

Line chart of Lyell Immunopharma Inc. (LYEL) daily closes from Jul 6, 2026 to Nov 12, 2026, with the offering filing on Nov 13, 2026 marked.

Cash and dilution

It reported cash of $92.1M as of Sep 30, 2026. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)

At its recent quarterly burn rate that cash lasts about 7.9 months, by our estimate from its XBRL cash flows. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)

Its share count rose 15.9% over the past year. (Company health, computed by us from SEC filings and XBRL, Oct 30, 2026)

The stock

The Nasdaq screener puts its market value at $351.6M. (Nasdaq stock screener, Nov 13, 2026)

Follow it up

The company's page on MarginsX, with its filings, health check and ownership. (capital.sophiaxt.com/stocks/LYEL)

The filing on SEC EDGAR. (sec.gov)

The filing in the MarginsX reader. (MarginsX reader)

Automated from SEC filings and market data by the MarginsX Data Desk, written by template with no AI. For information only. Not investment advice.

Facts behind this article

FactValueSourceAs of
NameLyell Immunopharma Inc.Source2026-11-13
FormS-3Source2026-11-13
FiledNov 13, 2026Source2026-11-13
WhoLyell Immunopharma Inc. (LYEL)Source2026-11-13
SymbolLYELSource2026-11-13
Cash92,053,000 USDSource2026-09-30
Cash dateSep 30, 2026Source2026-09-30
Runway7.9 monthsSource2026-09-30
Dilution 1y15.9 %Source2026-10-30
Cap351,573,580 USDSource2026-11-13

Sources

Automated from SEC filings and market data. No AI. For information only. Not investment advice.

Discuss in MarginsX More from the Data Desk

More on MarginsX

Companies in this article

Topics

Related Data Desk stories

Every Data Desk article: /desk · RSS